TY - JOUR
T1 - Small Cell Lung Cancer, Version 2.2022
AU - Ganti, Apar Kishor P.
AU - Loo, Billy W.
AU - Bassetti, Michael
AU - Blakely, Collin
AU - Chiang, Anne
AU - D'Amico, Thomas A.
AU - D'Avella, Christopher
AU - Dowlati, Afshin
AU - Downey, Robert J.
AU - Edelman, Martin
AU - Florsheim, Charles
AU - Gold, Kathryn A.
AU - Goldman, Jonathan W.
AU - Grecula, John C.
AU - Hann, Christine
AU - Iams, Wade
AU - Iyengar, Puneeth
AU - Kelly, Karen
AU - Khalil, Maya
AU - Koczywas, Marianna
AU - Merritt, Robert E.
AU - Mohindra, Nisha
AU - Molina, Julian
AU - Moran, Cesar
AU - Pokharel, Saraswati
AU - Puri, Sonam
AU - Qin, Angel
AU - Rusthoven, Chad
AU - Sands, Jacob
AU - Santana-Davila, Rafael
AU - Shafique, Michael
AU - Waqar, Saiama N.
AU - Gregory, Kristina M.
AU - Hughes, Miranda
N1 - Publisher Copyright:
© National Comprehensive Cancer Network, Inc. 2021.
PY - 2021/12
Y1 - 2021/12
N2 - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management for patients with SCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. This selection for the journal focuses on metastatic (known as extensive-stage) SCLC, which is more common than limited-stage SCLC. Systemic therapy alone can palliate symptoms and prolong survival in most patients with extensive-stage disease. Smoking cessation counseling and intervention should be strongly promoted in patients with SCLC and other high-grade neuroendocrine carcinomas. The “Summary of the Guidelines Updates” section in the SCLC algorithm outlines the most recent revisions for the 2022 update, which are described in greater detail in this revised Discussion text.
AB - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management for patients with SCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. This selection for the journal focuses on metastatic (known as extensive-stage) SCLC, which is more common than limited-stage SCLC. Systemic therapy alone can palliate symptoms and prolong survival in most patients with extensive-stage disease. Smoking cessation counseling and intervention should be strongly promoted in patients with SCLC and other high-grade neuroendocrine carcinomas. The “Summary of the Guidelines Updates” section in the SCLC algorithm outlines the most recent revisions for the 2022 update, which are described in greater detail in this revised Discussion text.
UR - http://www.scopus.com/inward/record.url?scp=85122359913&partnerID=8YFLogxK
U2 - 10.6004/JNCCN.2021.0058
DO - 10.6004/JNCCN.2021.0058
M3 - Article
C2 - 34902832
AN - SCOPUS:85122359913
SN - 1540-1405
VL - 19
SP - 1441
EP - 1464
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 12
ER -